title: Academic-industrial partnerships in drug discovery in the age of genomics.
abstract: Many US FDA-approved drugs have been developed through productive interactions between the biotechnology industry and academia. Technological breakthroughs in genomics, in particular large-scale sequencing of human genomes, is creating new opportunities to understand the biology of disease and to identify high-value targets relevant to a broad range of disorders. However, the scale of the work required to appropriately analyze large genomic and clinical data sets is challenging industry to develop a broader view of what areas of work constitute precompetitive research.
authors.affiliation: Biogen, 225 Binney Street, Cambridge, MA 02142, USA. Electronic address: tim.harris@biogen.com.
authors.forename: Tim
authors.initials: T
authors.lastname: Harris
authors.affiliation: Biogen, 225 Binney Street, Cambridge, MA 02142, USA.
authors.forename: Stelios
authors.initials: S
authors.lastname: Papadopoulos
authors.affiliation: Institute for Genomic Medicine, Columbia University Medical Center, New York, NY 10032, USA.
authors.forename: David B
authors.initials: DB
authors.lastname: Goldstein
mesh_terms: D000047:Academies and Institutes / Q000639:trends; D001709:Biotechnology / Q000639:trends; D055808:Drug Discovery / Q000639:trends*; D004345:Drug Industry / Q000639:trends*; D015894:Genome, Human; D023281:Genomics; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D012106:Research / Q000639:trends
keywords: academic collaborations; drug discovery; genomics